OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY. (1st June 2021)

• Record Type: Journal Article
• Authors: Mochizuki, Aaron; Ramakrishna, Sneha; Good, Zina; Patel, Shabnum; Chinnasamy, Harshini; Yeom, Kristen; Schultz, Liora; Richards, Rebecca; Campen, Cynthia; Reschke, Agnes; Mahdi, Jasia; Toland, Angus; Baggot, Christina; Mavroukakis, Sharon; Egeler, Emily; Moon, Jennifer; Landrum, Kayla; Erickson, Courtney; Rasmussen, Lindsey; Barsan, Valentin; Tamaresis, John; Marcy, Anne; Kunicki, Michael; Celones, Michelle; Ehlinger, Zach; Kurra, Sreevidya; Cornell, Timothy; Partap, Sonia; Fisher, Paul; Grant, Gerald; Vogel, Hannes; Davis, Kara; Feldman, Steven; Sahaf, Bita; Majzner, Robbie; Mackall, Crystal; Monje, Michelle;
• Is Part Of: Neuro-oncology. Volume 23(2021)Supplement 1
• Page Start: i39
• Page End: i39
• Publication Date: 2021-06-01
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab090.158
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Introduction: We are conducting a Phase I clinical trial utilizing chimeric antigen receptor (CAR) T-cells targeting GD2 (NCT04196413) for H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) and spinal cord diffuse midline glioma (DMG). Cerebrospinal fluid (CSF) is collected for correlative studies at the time of routine intracranial pressure monitoring via Ommaya catheter. Here we present single cell RNA-sequencing results from the first 3 subjects. Methods: Single cell RNA-sequencing was performed utilizing 10X Genomics on cells isolated from CSF at various time points before and after CAR T-cell administration and on the CAR T-cell product. Output was aligned with Cell Ranger and analyzed in R. Results: As detailed in the Majzner et al. abstract presented at this meeting, three of four subjects treated at dose-level one exhibited clear radiographic and/or clinical benefit. We have to date completed single cell RNA-sequencing for three of these four subjects (two with benefit, one without). After filtering out low-quality signals and doublets, 89, 604 cells across 3 subjects were analyzed. Of these, 4, 122 cells represent cells isolated from CSF and 85, 482 cells represent CAR T-cell product. Two subjects who demonstrated clear clinical and radiographic improvement exhibited fewer S100A8 + S100A9 + myeloid suppressor-cells and CD25 + FOXP3 + regulatory T-cells in the CSF pre-infusion compared to the subject who did not derive a therapeutic response. In one subject with DIPG who demonstrated improvement, polyclonal CAR T-cells detectable in CSF at Day +14 demonstrated enrichment of CD8A, GZMA, GNLY and PDCD1 compared to the pre-infusion CAR T-cells by trajectory analysis, suggesting differentiation toward a cytotoxic phenotype; the same subject exhibited increasing numbers of S100A8 + S100A9 + myeloid cells and CX3CR1 + P2RY12 + microglia over time. Further analyses will be presented as data become available. Conclusions: The presence of immunosuppressive myeloid populations, detectable in CSF, may correlate to clinical response in CAR T cell therapy for DIPG/DMG.